Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With MK-1775 in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

Trial Profile

A Randomized Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With MK-1775 in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adavosertib (Primary) ; Gemcitabine (Primary)
  • Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Aug 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
    • 20 Aug 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
    • 04 Jun 2019 Primary endpoint (Progression free survival) has been met as per result presented at the 55th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top